DENVER, CO—With several P2Y12 inhibitors available, clinicians are increasingly faced with choices about whether to switch their patients with ACS or a recent stent implantation from one to another, ...
December 18, 2009 (Durham, North Carolina) — Initial phase 2 results with a new antiplatelet agent that has both intravenous and oral formulations have been published [1]. The agent, elinogrel ...
When stopping dual antiplatelet therapy (DAPT) after PCI, it appears that a P2Y12 inhibitor is a better option than aspirin for continuing monotherapy, a network-meta-analysis suggests. The risk of MI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results